The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: IgG gene expressing animal models.
However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.
Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.
110 innovations will shape the pharmaceutical industry
According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.
Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1 therapies, which are now well established in the industry.
Innovation S-curve for the pharmaceutical industry
IgG gene expressing animal models is a key innovation area in the pharmaceutical industry
IgG is the most abundant immunoglobulin found in the bloodstream and plays a major role in linking foreign particles to innate immune cells. IgG antibody responses are a useful marker of antigen exposure to diagnose immunodeficiency. To obtain human antibody responses within a mouse, mice are genetically engineered to be humanised for their Ig genes. KO-plus-transgenic humanisation involves generating genetically engineered (HumAb) mice by disrupting the endogenous mouse Ig genes and simultaneously introducing human Ig transgenes at a different and random location.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 90+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of IgG gene expressing animal models.
Key players in IgG gene expressing animal models – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Regeneron Pharmaceuticals is the leading patent filer in IgG gene expressing animal models. Regeneron has a market cap of $78.64 billion and is primarily focused on cancer, allergic and inflammatory diseases, eye diseases, metabolic and cardiovascular diseases, infectious diseases, neuromuscular diseases, and rare diseases. The company accelerates antibody target discovery and validation through its invented technology such as VelociSuite technologies, VelociGene and VelociMouse for disease modelling and target exploration. In 2022, AbCellera entered into a collaboration agreement with Regeneron for four discovery programmes based on AbCellera’s antibody discovery engine and Regeneron’s VelocImmune mice.
In terms of application diversity, Vivoryon Therapeutics is the top company, followed by MannKind, and Onxeo SA. By means of geographic reach, Sangamo Therapeutics holds the top position, while Ligand Pharmaceuticals and Denali Therapeutics stand in the second and third position, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
#leading #innovators #IgG #gene #expressing #animal #models #pharmaceutical #industry